MEDIROM Files Annual Report, Temporarily Delays Nasdaq Delisting
Key Facts
MEDIROM Healthcare Technologies said on November 18 that it had received a Nasdaq notice on November 13 for failing to file its annual Form 20-F for the year ended December 31, 2025, by the extended deadline, leaving it out of compliance with periodic reporting requirements. The company said it requested a hearing on November 18 and filed its annual report with the U.S. Securities and Exchange Commission the same day. The notice said trading would be suspended and its American depositary shares delisted at the open on November 24 if the company did not request an appeal. The hearing request automatically stays the suspension for 15 days from the date it is filed. MEDIROM asked the panel to extend the stay through the end of the hearing process, and requested continued listing of its shares on Nasdaq.
Filing the report is a step toward addressing the reporting violation that led to the delisting notice, but a decision on continued listing has not yet been made. The company submitted the report to Nasdaq in support of its appeal, but did not guarantee the exchange would consider the filing sufficient to regain compliance. It also did not guarantee that the hearing panel would grant an additional stay of the suspension or allow the listing to continue. The automatic stay limits the risk of a trading suspension for a defined period, while any extension depends on the panel's decision. The company's request therefore remains under review despite the annual report filing.
MEDIROM also faces a separate violation of Nasdaq's minimum bid price requirements under Rule 5550(a)(2). The violation stems from the closing bid price remaining below $1 for 31 consecutive business days, from August 24 to October 5, 2026. To regain compliance, the closing bid price must be at least $1 for 10 consecutive business days. Nasdaq set April 5, 2027, as the deadline to regain compliance with this requirement. The company said the annual report filing does not address the price violation, leaving that compliance track separate from the appeal of the delisting decision related to reporting.
The reporting problem began before the November notice: Nasdaq notified the company on May 26, 2026, that it was out of compliance with periodic reporting requirements. The exchange gave it an extension until November 12 to file the report and regain compliance. The November 13 notice followed the expiration of that deadline without the required annual report being filed. The report covers the fiscal year ended December 31, 2025, and was filed on November 18, 2026. These dates show that the company addressed the delay after receiving the delisting notice, while the appeal outcome and listing proceedings remain pending.
The reporting delay coincided with weak financial results in fiscal 2025. The company recorded a net loss of ¥3,642,581 thousand, compared with net income of ¥138,191 thousand in fiscal 2024. It also reported negative operating cash flow of ¥1,155,007 thousand in 2025. MEDIROM said the loss and declines in working capital and shareholders' equity, together with its need for additional funding, raise substantial doubt about its ability to continue as a going concern. These financial disclosures add context to the company's pressures without changing the separate nature of the bid price violation and the annual report issue.
The group operates about 281 wellness salons under the Re.Ra.Ku brand across Japan, according to its November 18 statement. The company also disclosed that it terminated its plan to acquire 70% of Japan Gene Medicine Corporation by mutual agreement reached on October 31, 2026. The transaction had been based on a share transfer agreement dated June 30, 2024. In the market, MRM closed at $0.2738 on November 17, after closing at $0.2802 on November 16, $0.277 on November 13, and $0.2836 on November 12. This sequence shows the closing prices in the cited sessions, while the company's next step remains tied to the hearing panel's decision and the separate deadline to regain compliance with the price requirement.